Medtronic

Medtronic uses two primary channels: an internal R&D budget of roughly $2.7 billion annually and strategic corporate development, which includes minority investments through Medtronic Ventures and full acquisitions. The Ventures arm operates much like a traditional corporate VC, taking equity stakes in early-to-growth-stage medtech firms, with a pathway to eventual acquisition if the technology proves clinically viable.

Medtronic is legally incorporated in Ireland with its principal executive office in Galway, a structure resulting from the 2015 Covidien inversion merger. Its operational headquarters, including the C-suite and core management functions, remain at 710 Medtronic Parkway in Minneapolis, Minnesota. This dual structure optimizes its global tax position while preserving its historic US operating base.

Medtronic tends to acquire companies that have achieved regulatory clearance or are in late-stage clinical trials for technologies adjacent to its four core cardiovascular, neuroscience, medical-surgical, and diabetes groups. Early-stage investments through Medtronic Ventures are typically minority positions where the strategic value — a novel algorithm, a sensor technology, or a minimally invasive tool — complements an existing Medtronic platform.

Chairman and CEO Geoff Martha, who assumed the role in April 2020, oversees the corporate development function as part of his enterprise portfolio. Day-to-day M&A and venture decisions are delegated to the corporate development team and the head of Medtronic Ventures, who report through the CFO. Major acquisitions require board approval.

Yes. The Medtronic Foundation is a legally separate philanthropic entity focused on expanding healthcare access in underserved communities globally. Additionally, co-founder Earl Bakken established the Earl and Doris Bakken Foundation and the Bakken Family WRC Foundation, which are independent of Medtronic's corporate venture and M&A activity.